DRUG
Price
$37.88
Change
-$1.87 (-4.70%)
Updated
Dec 18, 04:59 PM (EDT)
ORYZF
Price
$1.79
Change
+$0.10 (+5.92%)
Updated
Dec 17 closing price
Ad is loading...

DRUG vs ORYZF

Header iconDRUG vs ORYZF Comparison
Open Charts DRUG vs ORYZFBanner chart's image
Bright Minds Biosciences
Price$37.88
Change-$1.87 (-4.70%)
Volume$308
CapitalizationN/A
Oryzon Genomics SA
Price$1.79
Change+$0.10 (+5.92%)
Volume$500
CapitalizationN/A
DRUG vs ORYZF Comparison Chart
Loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DRUG vs. ORYZF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Buy and ORYZF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (DRUG: $39.75 vs. ORYZF: $1.79)
Brand notoriety: DRUG and ORYZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 2% vs. ORYZF: 25%
Market capitalization -- DRUG: $275.39M vs. ORYZF: $111.02M
DRUG [@Biotechnology] is valued at $275.39M. ORYZF’s [@Biotechnology] market capitalization is $111.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileORYZF’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • ORYZF’s FA Score: 1 green, 4 red.
According to our system of comparison, ORYZF is a better buy in the long-term than DRUG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 3 TA indicator(s) are bullish while ORYZF’s TA Score has 3 bullish TA indicator(s).

  • DRUG’s TA Score: 3 bullish, 2 bearish.
  • ORYZF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, DRUG is a better buy in the short-term than ORYZF.

Price Growth

DRUG (@Biotechnology) experienced а +6.40% price change this week, while ORYZF (@Biotechnology) price change was +10.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

DRUG is expected to report earnings on Aug 28, 2023.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DRUG($275M) has a higher market cap than ORYZF($111M). DRUG YTD gains are higher at: 2679.720 vs. ORYZF (5.294). ORYZF has higher annual earnings (EBITDA): 834K vs. DRUG (-3.54M). ORYZF has more cash in the bank: 8.44M vs. DRUG (6.19M). DRUG has less debt than ORYZF: DRUG (14K) vs ORYZF (13.4M). DRUG (0) and ORYZF (0) have equivalent revenues.
DRUGORYZFDRUG / ORYZF
Capitalization275M111M248%
EBITDA-3.54M834K-425%
Gain YTD2679.7205.29450,617%
P/E RatioN/AN/A-
Revenue00-
Total Cash6.19M8.44M73%
Total Debt14K13.4M0%
TECHNICAL ANALYSIS
Technical Analysis
DRUGORYZF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
25%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
20%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
20%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
16%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
7%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
N/A
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
82%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORYZF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRWG1.720.01
+0.58%
GrowGeneration Corp
CGC3.050.01
+0.33%
Canopy Growth Corp
SITC15.42-0.07
-0.45%
SITE Centers Corp
APTO0.19N/A
-0.85%
Aptose Biosciences
GGG86.21-1.22
-1.40%
Graco

ORYZF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORYZF has been loosely correlated with CLDI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORYZF jumps, then CLDI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
+5.92%
CLDI - ORYZF
37%
Loosely correlated
-1.14%
PPBT - ORYZF
28%
Poorly correlated
+1.03%
DRUG - ORYZF
25%
Poorly correlated
+2.40%
GNNSF - ORYZF
24%
Poorly correlated
N/A
IPSC - ORYZF
20%
Poorly correlated
N/A
More